Navigation Links
Vigilant Biosciences to Present at Medtech Showcase 2017 and BioLink 2017 China Healthcare Industry Investment and Licensing Conference
Date:1/6/2017

FORT LAUDERDALE, Fla., Jan. 6, 2017 /PRNewswire/ --  Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced that Matthew H.J. Kim, Founder, Chairman and Chief Executive Officer, will present at two upcoming conferences in San Francisco: the BioLink 2017 China Healthcare Industry Investment and Licensing Conference, taking place January 8, 2017 at the San Francisco Hilton Airport Hotel, and Medtech Showcase 2017 (at Biotech Showcase™), taking place at the Parc 55 San Francisco, January 10 – 11, 2017.

Mr. Kim will speak at the BioLink 2017 conference on Sunday, January 8 at 3:30 p.m. PST, and will speak at the Medtech Showcase 2017 on Wednesday, January 11 at 10:15 a.m. PST. In his presentations, Mr. Kim will review Vigilant Biosciences' business strategy and opportunities in regards to the commercialization of its OncAlert® Oral Cancer and OncAlert Labs product lines, as well as other products in the Company's pipeline.

About Vigilant Biosciences Products
Vigilant Biosciences OncAlert Oral Cancer product line is based on patented technology that measures soluble CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. Vigilant's products currently include the OncAlert Labs OraMark™ Test, a laboratory developed test available only through OncAlert Labs, a CLIA certified laboratory; and the OncAlert Oral Cancer product line, which includes the OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test, both CE Marked and available in select markets outside the United States.

Vigilant's accurate, cost-effective tests can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus).

About Oral Cancer
According to the World Health Organization, there are more than 529,000 new cases of oral (lip, oral cavity and pharynx) cancer each year worldwide, with mortality rates that reach up to 292,000 deaths each year. In the United States, more than 48,000 individuals will be diagnosed with oral cancer this year with more than 9,500 deaths resulting from this disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. For those who survive oral cancer diagnosed in the later stages, the treatment is painful, debilitating and often disfiguring. In addition, patients often struggle with eating and drinking, communicating and self image. Early detection (stage I and II) of oral cancer yields survival rates of up to 90 percent.

For more information or to set up a meeting with Vigilant Biosciences at BioLink 2017 or Medtech Showcase 2017, please contact Jennifer Moritz at jmoritz@0to5.com.

About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer product line and OncAlert Labs product line include point-of-care and lab-based products and services that are simple, accurate and cost-effective and that can empower healthcare practitioners to improve potential outcomes through earlier intervention. The OncAlert Oral Cancer LAB Test and the OncAlert Oral Cancer RAPID Test are CE Marked and available in select international markets outside the U.S. The OraMark Test is a Laboratory Developed Test that is only available in the U.S. exclusively through OncAlert Labs, LLC, a CLIA-certified laboratory and a member of the Vigilant Biosciences family of companies. For more information, visit www.vigilantbiosciences.com and www.oncalertlabs.com.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vigilant-biosciences-to-present-at-medtech-showcase-2017-and-biolink-2017-china-healthcare-industry-investment-and-licensing-conference-300386755.html


'/>"/>
SOURCE Vigilant Biosciences, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Vigilant Biosciences Announces Poster Session on Risk Stratification System for Oral Cancer Screening at Inaugural Global Oral Cancer Forum
2. Vigilant Biosciences, Inc. Expands Board of Directors with Esteemed Dental Professional Dr. Linda Niessen
3. Vigilant Biosciences, Inc. Expands Executive Leadership Team and Board of Directors with Veteran Biotechnology and Diagnostics Executives
4. Avidity Biosciences Announces Publication on Targeting Therapeutic Oligonucleotides by Arthur A. Levin in the New England Journal of Medicine
5. Biotech Stocks on Investors Radar -- Eleven Biotherapeutics, Illumina, Sangamo Biosciences, and CytRx
6. Neurocrine Biosciences Announces Chief Financial Officer Timothy P. Coughlin to Step Down
7. DuPont Industrial Biosciences to Begin New Research Aimed to Enable Global Access for Protein Medications
8. Roche announces termination of 2013 Development, Commercialization and License Agreement with Pacific Biosciences
9. ACEA Biosciences Presents Efficacy and Safety Data From AC0010 Phase I/II Clinical Trial for Treatment of Advanced Non-Small Cell Lung Cancer at the WCLC 2016 Conference
10. ACEA Biosciences Announces Data Presentation at WCLC 2016 Conference: New AC0010 Data to Be Presented
11. Vigene Biosciences Acquires the cGMP Manufacturing Facility and Assets of Omnia Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and ... San Diego Rotary Club. The event entitled “Stem Cells and Their ... 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... 13 prestigious awards honoring scientists who have made outstanding contributions to ... symposium during Pittcon 2018, the world’s leading conference and exposition for laboratory science, ...
Breaking Biology Technology:
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
Breaking Biology News(10 mins):